Morphogenics is a broad-based proprietary platform technology that regulates the ability of a host organism to repair mutations that occur during DNA replication. All proliferating cells duplicate their genetic material prior to dividing into two siblings (‘sibs”). During the replication process, thousands of mutations occur that are corrected prior to cell division by DNA repair mechanisms. One of the most robust repair mechanisms is the highly conserved process called mismatch repair (“MMR”), which proofreads newly replicated DNA for mutations. The process is similar to a computer spell check function. Once the MMR process is completed and mutations in the new genome have been corrected, the cell divides into two genetically identical sibs. Cells with dysfunctional MMR accumulate mutations throughout their genomes leading to mutant gene(s) that yield sibs with traits different from that of the parent.

The selective regulation of the MMR function via morphogenics results in an unbiased, undirected and accelerated rate of genetic evolution within a living host organism. This unique feature makes morphogenics a highly desirable technology for creating molecules with biologically important and commercially attractive traits.

Morphotek has leveraged morphogenics through the following applications:

• Human MORPHODOMA^® technology employs an ex vivo immunization process in combination with morphogenics to generate fully human antibodies targeted against disease-associated antigens. The resultant antibodies bypass all the third party royalties required by recombinant antibody technologies.

• Libradoma™ technology generates libraries of hybridomas that can be rapidly screened to identify fully human monoclonal antibodies to known antigens and novel targets for the diagnosis and treatment of diseases in humans. As with Human MORPHODOMA, the resultant antibodies bypass all the third party royalties required by alternative antibody technologies (i.e., humanization, transgenic and phage platforms).

Morphogenics technology has been validated though research collaborations with premier corporate partners including Abgenix, Amgen, Centocor, Novo Nordisk, PDL, GSK, Tanox, and Wyeth, as well as though its application to internal development candidates “MORAb-003” and “MORAb-009” which were optimized for affinity and titers, respectively.

Download Morphotek BioProcess Article.

Download the Human B-Cell Hybridoma Technology.